Virios Therapeutics announces dosing of first patient in IMC-2 Long-COVID treatment trial
Aug. 15, 2022
Virios Therapeutics, Inc. announced commencement of enrollment in its exploratory Long-COVID trial.
The trial will assess the safety and effectiveness of antiviral therapy with Virios’ second development combination, IMC-2 (valacyclovir + celecoxib), to treat the symptoms associated with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function and overall health improvement. IMC-2 is a novel, dual mechanism antiviral therapy combining valacyclovir and celecoxib designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.
